Gene · 25833
Papers1,618
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 1,618
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clustering malignant cell states using universally variable genes. | Brief Bioinform | 2023 | 38084922 | PubTator, text mining | PubMed |
| Deciphering the role of immunoglobulin secreting malignant lineages in the invasive frontiers of small cell lung cancer by scRNA-seq and spatial transcriptomics analysis. | Cell Discov | 2023 | 38081849 | PubTator, text mining | PubMed |
| Clonality Analysis for the Relationship between the Pulmonary Combined Neuroendocrine Carcinoma and "the So-Called Reported Histologic Transformation". | Cancers (Basel) | 2023 | 38067352 | PubTator, text mining | PubMed |
| Musashi-1 Is a Novel Immunohistochemical Marker of Neuroendocrine Carcinoma of the Lung. | Cancers (Basel) | 2023 | 38067335 | PubTator, text mining | PubMed |
| Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report. | BMC Pulm Med | 2023 | 38057798 | PubTator, text mining | PubMed |
| Metabolomic signatures associated with pathological angiogenesis in moyamoya disease. | Clin Transl Med | 2023 | 38037492 | PubTator, text mining | PubMed |
| Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of circulating biomarkers. | Front Immunol | 2023 | 38022574 | PubTator, text mining | PubMed |
| Role of Inorganic Fillers on the Physical Aging and Toughness Loss of PLLA/BaSO4 Composites. | ACS Appl Polym Mater | 2023 | 38021210 | PubTator, text mining | PubMed |
| Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer. | Breast Cancer Res | 2023 | 38017485 | PubTator, text mining | PubMed |
| Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1. | Cell Rep Med | 2023 | 37992688 | PubTator, text mining | PubMed |
| Additive manufacturing of poly (lactic acid)/hydroxyapatite/carbon nanotubes biocomposites for fibroblast cell proliferation. | Sci Rep | 2023 | 37990057 | PubTator, text mining | PubMed |
| Molecular signature to predict quality of life and survival with glioblastoma using Multiview omics model. | PLoS One | 2023 | 37972206 | PubTator, text mining | PubMed |
| Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases. | Signal Transduct Target Ther | 2023 | 37953273 | PubTator, text mining | PubMed |
| Mapping the genomic landscape of multidrug resistance in Plasmodium falciparum and its impact on parasite fitness. | Sci Adv | 2023 | 37939186 | PubTator, text mining | PubMed |
| Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. | Lung Cancer | 2023 | 37931445 | PubTator, text mining | PubMed |
| Human airway tuft cells influence the mucociliary clearance through cholinergic signalling. | Respir Res | 2023 | 37925434 | PubTator, text mining | PubMed |
| Data-driven structural analysis of small cell lung cancer transcription factor network suggests potential subtype regulators and transition pathways. | NPJ Syst Biol Appl | 2023 | 37907529 | PubTator, text mining | PubMed |
| Platelet Glycoprotein Receptor Ia-C807T and IIIa-PlA1/PlA2 Genetic Polymorphisms Are Associated With Enhanced Platelet Function in Women With Recurrent Miscarriages. | Cureus | 2023 | 37899902 | PubTator, text mining | PubMed |
| A tuft cell - ILC2 signaling circuit provides therapeutic targets to inhibit gastric metaplasia and tumor development. | Nat Commun | 2023 | 37898600 | PubTator, text mining | PubMed |
| Proteomic Profiling of Small-Cell Lung Cancer: A Systematic Review. | Cancers (Basel) | 2023 | 37894372 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25833/papers?page=12